Thynk Capital

IMX Health is the first financial futures exchange for the healthcare industry. In addition to offering hedging opportunities for payers, providers, and other market participants in the healthcare industry, IMX will create a transparent, two-sided market for pricing healthcare assets. Patients will also benefit from increased competition for services and lower prices and premiums as a result of this.

IVIVA Medical was founded with the goal of developing autologous tissue constructs as a solution to end-state renal disease (ESRD). End-stage renal disease affects over 500,000 patients in the United States and despite transplant being the only definitive treatment for ESRD, most will never receive a donor kidney. Our team is leveraging emerging complementary technologies in tissue engineering, 3D additive manufacturing, and stem cell biology in order to realize the potential of regenerative medicine to end donor organ shortage. We are developing bioartificial platforms and systems not only to provide therapies but to serve as the foundational building blocks for the next generation of engineered functionalized tissues.

Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”). Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.

Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading platform. Its platform technology aims to reverse atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.

Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading platform. Its platform technology aims to reverse atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.

KitoTech Medical is a medical device company developing and commercializing products for wound closure and wound care. It has developed and introduced a revolutionary proprietary wound closure product, microMend, onto the market. It incorporates tiny Microstaples on an adhesive backing, which is the size and shape of a butterfly bandage. microMend is painless and as easy to apply as a bandage. The Microstaples provide the holding strength of sutures resulting in secure anchoring of the device to the skin. These features make microMend ideal for closing surgical incisions and lacerations currently closed with sutures and staples. Clinical studies have demonstrated its superiority over sutures in terms of clinical outcomes, including cosmetic results. It is much faster than sutures and can be applied by less costly medical personnel (nurses, PAs, and nursing assistants) translating into significant cost savings in wound closure procedures. microMend is being marketed in a broad range of surgical specialties as well as dermatology and emergency medicine. The military represents an additional major market for microMend, where the product is also being commercialized. Its potential market is over $600M and $2B in the US and worldwide, respectively. KitoTech Medical was founded in 2011 and is based in Seattle, Washington.

Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues. Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease.

Theragene Pharmaceuticals combines innovative science and efficiency to develop life-saving therapies for many debilitating diseases. As a biopharmaceutical company operating in both the US and Asia, it delivers unique product development models, utilizing the strengths of each region, while delivering safe, effective treatments. Its mission is to provide cutting-edge science, through resourceful product models, that significantly advance each product from the preclinical stage to finished product. From advancements in oncology to novel drug formulations, they are developing tomorrow's medicine.

KLOTHO Therapeutics (KTI) is a biotechnology company developing patent-pending Klotho proteins with great potential to redefine society’s experience with aging. Klotho, a naturally occurring human protein discovered in 1997, promises to delay major diseases of aging – kidney failure, Alzheimer’s, osteoporosis, cancer, hypertension and diabetes, according to published studies. For example, National Institutes of Health report Klotho-deficient animals live 25% shorter and look older while animals overexpressing Klotho live 20-30% longer. The company’s first focus is on kidney failure, one of the major causes of death in the U.S. that affects up to 30 million people per year, 600,000 of whom are currently on dialysis. There is no successful long-term therapy today. KTI has filed patents on modified Klotho proteins covering its expansive potential indications.

Fisker is a designer and manufacturer of emotion-stirring, eco-friendly electric vehicles. The company is on a mission to become an e-mobility service provider with sustainable vehicles because it is passionately motivated by a vision of a clean future for everyone.

Curtana Pharmaceuticals was founded on a mission to develop the first truly targeted therapies for the treatment of the most aggressive types of brain cancer. The company’s drug development program is based on the pioneering research of Dr. Santosh Kesari, who is currently the Chairman of the Department of Translational Neuro-oncology and Neuro-therapeutics at the John Wayne Cancer Institute. Curtana’s senior leadership brings years of experience in the pharmaceutical industry, with extensive backgrounds in the development of new molecular entities for the treatment of cancer as well as CNS disorders. Curtana initiated operations in San Diego, California in 2013. Following the award of a highly prestigious and competitive grant ($7.6M) from the Cancer Prevention and Research Institute of Texas (CPRIT) in August 2014, the company relocated its lab and offices to Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, and other anonymous investors.

WinSanTor Inc. is a clinical-stage biotechnology company focused on the discovery and development of treatments for peripheral neuropathies.

Lubris BioPharma is a biopharmaceutical company developing recombinant human lubricin for the treatment of dry eye, osteoarthritis, and other age and inflammation-related conditions. it is produced throughout the human body protecting tissues and other surfaces from friction-related damage and wear.